You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

I-cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sickle Cell Disease Trial in Atlanta, Cincinnati (I-STRONG for SCD)

Recruiting
  • Sickle Cell Disease
  • I-STRONG for SCD
  • Atlanta, Georgia
  • +1 more
Oct 26, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023

Metastatic Clear Cell Renal Cell Carcinoma, With Positive PSMA Expression at Tumor Sites Trial (177Lu-PSMA-1

Not yet recruiting
  • Metastatic Clear Cell Renal Cell Carcinoma
  • With Positive PSMA Expression at Tumor Sites
  • 177Lu-PSMA-1 (radiopharmaceutical)
  • (no location specified)
Sep 26, 2023

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +4 more
  • Birmingham, United Kingdom
  • +5 more
Sep 18, 2023

Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

Not yet recruiting
  • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
  • New York, New York
    NYU Langone Health
Apr 4, 2023

Refractory B-cell Acute Lymphoblastic Leukemia Trial in Houston (Mosunetuzumab)

Not yet recruiting
  • Refractory B-cell Acute Lymphoblastic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

Hand, Foot and Mouth Disease, Herpangina Trial in Chuxiong (low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated,

Recruiting
  • Hand, Foot and Mouth Disease
  • Herpangina
  • low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
  • +3 more
  • Chuxiong, Yunnan, China
    Dayao County Center for Disease Control and Prevention
Sep 25, 2023

NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Phase I - Mirdametinib - Level 1
  • +4 more
  • (no location specified)
Jul 7, 2023

Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

Recruiting
  • Hairy Cell Leukemia
  • Hairy Cell Leukemia Variant
  • CD22CART cell infusion
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

COVID-19 Trial (Recombinant variant COVID-19 vaccine(Sf9 cell))

Not yet recruiting
  • COVID-19
  • Recombinant variant COVID-19 vaccine(Sf9 cell)
  • (no location specified)
Mar 10, 2023

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • (no location specified)
Aug 4, 2023

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

NSCLC Trial in France (TG6050)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Bordeaux, France
  • +3 more
Mar 15, 2023

Hepatocellular Carcinoma Trial in Jakarta Pusat (Autologous Natural Killer Cell Therapy, Clinimacs Plus)

Recruiting
  • Hepatocellular Carcinoma
  • Autologous Natural Killer Cell Therapy
  • Clinimacs Plus
  • Jakarta Pusat, Jakarta, Indonesia
    Cipto Mangunkusumo General Hospital
Sep 24, 2023

Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer Trial in Nashville (drug, biological, radiation, procedure)

Not yet recruiting
  • Extensive Stage Lung Small Cell Carcinoma
  • Stage IV Lung Cancer
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Oct 25, 2023

Solid Tumors Trial (IBR854 Cell Injection)

Not yet recruiting
  • Solid Tumors
  • IBR854 Cell Injection
  • (no location specified)
Aug 14, 2023

Angiosarcoma Trial in Houston (Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A)

Not yet recruiting
  • Angiosarcoma
  • Houston, Texas
    M D Anderson Cancer Center
Mar 23, 2023

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)

Not yet recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • JS203 for Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 11, 2022

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023